Which of the following drugs inhibits platelet cyclooxygenase reversibly
**Question:** Which of the following drugs inhibits platelet cyclooxygenase reversibly?
*A. Aspirin*
*B. Clopidogrel*
*C. Ticlopidine*
*D. Vorapaxar*
**Core Concept:**
Cyclooxygenase (COX) is a key enzyme responsible for the conversion of arachidonic acid to prostaglandins and thromboxanes, which play significant roles in platelet activation and aggregation. Inhibition of COX leads to reduced platelet activation and aggregation, a crucial aspect of antiplatelet therapy.
**Why the Correct Answer is Right:**
Clopidogrel (B) is a widely used antiplatelet drug that irreversibly inhibits platelet COX-1, leading to a more sustained antiplatelet effect. However, due to its irreversible inhibition, there is a delayed onset of action and a variable response, making clopidogrel less suitable for patients with acute coronary syndromes.
**Why Each Wrong Option is Incorrect:**
**A. Aspirin (salicylic acid):**
Aspirin (acetylsalicylic acid) is a non-selective inhibitor of COX enzymes, causing both COX-1 and COX-2 inhibition. While aspirin is effective in preventing platelet aggregation, it irreversibly inhibits COX enzymes, resulting in a delayed platelet response and a higher risk of bleeding compared to clopidogrel.
**C. Ticlopidine (ticlopidine hydrochloride):**
Ticlopidine (C) is another irreversible COX-1 inhibitor, similar to aspirin. It has a similar drawback of delayed onset and increased bleeding risk due to its irreversible inhibition.
**D. Vorapaxar (vorapaxar):**
Vorapaxar (D) is a direct thrombin inhibitor, not an inhibitor of platelet COX enzymes. Therefore, it is not the correct answer for inhibiting platelet cyclooxygenase reversibly.
**Core Concept (Clinical Pearl):**
In patients requiring rapid and reversible platelet inhibition, clopidogrel is a better choice compared to aspirin, ticlopidine, or vorapaxar. Clopidogrel's reversible inhibition allows for a faster response and a lower risk of bleeding complications, making it suitable for patients with acute coronary syndromes or those who require temporary antiplatelet therapy.